Aminopyrimidines as SYK inhibitors

US8551984B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Merck Canada Inc. · CA

Inventors

• Michael D. Altman · Cambridge, US
• Brian M. Andresen · Sharon, US
• Kenneth L. Arrington · Philadelphia, US
• Jason Burch · Redwood City, US
• Kaleen Konrad Childers · Medfield, US
• Bernard Cote · Gatineau, CA
• Maria Emilia Di Francesco · Houston, US
• Anthony Donofrio · Cambridge, US
• Kristina Dupont-Gaudet · Vaudreuil-Dorion, CA
• John Michael Ellis · Needham, US
• Christian Fischer · Natick, US
• Daniel Guay · Churchill Falls, CA
• David Joseph Guerin · Natick, US
• Andrew M. Haidle · Cambridge, US
• Solomon D. Kattar · Arlington, US
• Sandra Lee Knowles · Princeton, US
• Chaomin Li · Boston, US
• Jongwon Lim · Lexington, US
• Michelle R. Machacek · Brookline, US
• Alan B. Northrup · Reading, US
• Brendan M. O'Boyle · Boston, US
• Ryan D. Otte · Natick, US
• Michael H. Reutershan · Watertown, US
• Eric T. Romeo · Brookline, US
• Adam J. Schell · Decatur, US
• Tony Siu · Brookline, US
• Kerrie Spencer · Woonsocket, US
• Brandon M. Taoka · Brookline, US
• B. Wesley Trotter · Medfield, US
• Hua Zhou · Acton, US

Key dates

• Filing date: Dec 15, 2010
• Grant date: Oct 8, 2013
• Expiry date: Apr 20, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/65583
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.